@article {Kuo2020.02.12.20022459, author = {Chia-Ling Kuo and Luke C. Pilling and Janice L. Atkins and George A. Kuchel and David Melzer}, title = {ApoE e2 and aging-related outcomes in 379,000 UK Biobank participants}, elocation-id = {2020.02.12.20022459}, year = {2020}, doi = {10.1101/2020.02.12.20022459}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {The Apolipoprotein E (APOE) e4 allele is associated with reduced longevity and increased Coronary Artery Disease (CAD) and Alzheimer{\textquoteright}s disease, with e4e4 having markedly larger effect sizes than e3e4. The e2 longevity promoting variant is less studied. We conducted a phenome-wide association study of ApoE e2e3 and e2e2 with aging phenotypes, to assess their potential as targets for anti-aging interventions. Data were from 379,000 UK Biobank participants, aged 40 to 70 years. e2e3 (n=46,535) had mostly lower lipid-related biomarker levels including reduced total and LDL-cholesterol, and lower risks of CAD (Odds Ratio=0.87, 95\% CI: 0.83 to 0.90, p=4.92{\texttimes}10-14) and hypertension (OR=0.94, 95\% CI: 0.92 to 0.97, p=7.28{\texttimes}10-7) versus e3e3. However, lipid changes in e2e2 (n=2,398) were more extreme, including a marked increase in triglyceride levels (0.41 Standard Deviations, 95\% CI: 0.37 to 0.45, p=5.42{\texttimes}10-92), with no associated changes in CAD risks. There were no associations with biomarkers of kidney function. The effects of both e2e2 and e2e3 were minimal on falls, muscle mass, grip strength or frailty. In conclusion, e2e3 has protective effects on some health outcomes, but the effects of e2e2 are not similar, complicating the potential usefulness of e2 as a target for anti-aging intervention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the National Institute on Aging (1R21AG060018-01).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis research conducted using the UK Biobank resource, under application 14631. UK Biobank received an approval from the UK Biobank Research Ethics Committee (REC) (REC reference 11/NW/0382). All the participants provided written informed consent to participate in the study and for their data to be used in future research. https://www.ukbiobank.ac.uk/}, URL = {https://www.medrxiv.org/content/early/2020/05/22/2020.02.12.20022459}, eprint = {https://www.medrxiv.org/content/early/2020/05/22/2020.02.12.20022459.full.pdf}, journal = {medRxiv} }